News

BBC News talked to Dr. Mikhail Kosiborod about new findings on the cardiovascular effects of semaglutide.

On average, survival benefits of CPR for cardiac arrest could be three times as high for white adults compared to Black adults and twice as high for men compared to women.

Semaglutide improves symptoms in both men and women who present with heart failure. When it comes to weight loss, however, the drug appears to benefit women much more than men.

The popular weight loss drug Wegovy seems to provide more health benefits for people who have diabetes and a common kind of heart failure than just helping take off the pounds, according to the results from the STEP HFpEF DM trial.

A new study led by Dr. Mikhail Kosiborod found patients with obesity-related heart failure and diabetes had a significant improvement in symptoms when taking semaglutide.

New study led by Saint Luke’s Mid America Heart Institute cardiologists reveals lower risk of all-cause and cause-specific mortality associated with higher docosahexaenoic acid (DHA) blood levels

During Heart Month, we are talking about atrial fibrillation, the recent changes in guidelines, and how Saint Luke’s is leading the way in innovative treatments for those who have a-fib.

Saint Luke’s Mid America Heart Institute was the first in Kansas and Missouri, and one of only 27 US institutions, to participate in PULSED AF clinical trial.

The groundbreaking STEP-HFpEF study, led by Mikhail Kosiborod, MD, vice president of research at Saint Luke's Health System, has been named one of the top advances by the American Heart Association.

TAVR in asymptomatic and minimally symptomatic patients is associated with a high survival rate, but relatively minor improvements, according to new research.